Patient individual phase gating for stereotactic radiation therapy of early stage non-small cell lung cancer (NSCLC).


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 03 2021
Historique:
received: 28 05 2020
accepted: 23 02 2021
entrez: 13 3 2021
pubmed: 14 3 2021
medline: 15 12 2021
Statut: epublish

Résumé

Stereotactic body radiotherapy (SBRT) applies high doses and requires advanced techniques to spare surrounding tissue in the presence of organ motion. In this work patient individual phase gating is investigated. We studied peripheral and central primary lung tumors. The internal target volume (ITV) was defined including different numbers of phases picked from a 4D Computed tomography (CT) defining the gating window (gw). Planning target volume (PTV) reductions depending on the gw were analyzed. A treatment plan was calculated on a reference phase CT (rCT) and the dose for each breathing phase was calculated and accumulated on the rCT. We compared the dosimetric results with the dose calculated when all breathing phases were included for ITV definition. GWs including 1 to 10 breathing phases were analyzed. We found PTV reductions up to 38.4%. The mean reduction of the lung volume receiving 20 Gy due to gating was found to be 25.7% for peripheral tumors and 16.7% for central tumors. Gating considerably reduced esophageal doses. However, we found that simple reduction of the gw does not necessarily influence the dose in a clinically relevant range. Thus, we suggest a patient individual definition of the breathing phases included within the gw.

Identifiants

pubmed: 33712667
doi: 10.1038/s41598-021-85031-w
pii: 10.1038/s41598-021-85031-w
pmc: PMC7955128
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5870

Références

Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1120-8
pubmed: 24661665
Support Care Cancer. 2013 Jan;21(1):211-8
pubmed: 22661073
Ann Lung Cancer. 2019;3(1):75-83
pubmed: 31942567
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):326-32
pubmed: 20117285
Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):253-60
pubmed: 16111596
Rep Pract Oncol Radiother. 2019 Jan-Feb;24(1):97-104
pubmed: 30532657
Radiother Oncol. 2010 Jul;96(1):48-54
pubmed: 20430460
J Natl Compr Canc Netw. 2017 Apr;15(4):504-535
pubmed: 28404761
Radiat Oncol. 2009 Jan 12;4:1
pubmed: 19138400
Radiat Oncol. 2018 Apr 2;13(1):57
pubmed: 29606150
Radiat Oncol. 2016 Sep 22;11(1):125
pubmed: 27659780
J Appl Clin Med Phys. 2010 Jun 29;11(3):3223
pubmed: 20717090
Pract Radiat Oncol. 2017 Sep - Oct;7(5):295-301
pubmed: 28596092
Radiother Oncol. 2009 Dec;93(3):430-5
pubmed: 19822373
Phys Med Biol. 2003 Jan 7;48(1):45-62
pubmed: 12564500
Lung Cancer (Auckl). 2018 Nov 05;9:103-110
pubmed: 30464667
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
J Clin Oncol. 2006 Oct 20;24(30):4833-9
pubmed: 17050868
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):618-25
pubmed: 19147026
J Thorac Oncol. 2008 Dec;3(12):1433-8
pubmed: 19057269
JAMA. 2010 Mar 17;303(11):1070-6
pubmed: 20233825
Radiother Oncol. 2010 May;95(2):172-7
pubmed: 20227779
Strahlenther Onkol. 2014 Jan;190(1):26-33
pubmed: 24052011
J Thorac Oncol. 2013 Aug;8(8):1050-8
pubmed: 23817193
J Thorac Dis. 2014 Apr;6(4):303-18
pubmed: 24688775
Clin Oncol (R Coll Radiol). 2014 Feb;26(2):67-80
pubmed: 24290238
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):967-73
pubmed: 21377293

Auteurs

K M Kraus (KM)

School of Medicine and Klinikum Rechts Der Isar, Department of Radiation Oncology, Technichal University of Munich (TUM), Munich, Germany. kimmelanie.kraus@mri.tum.de.

M Oechsner (M)

School of Medicine and Klinikum Rechts Der Isar, Department of Radiation Oncology, Technichal University of Munich (TUM), Munich, Germany.

J J Wilkens (JJ)

School of Medicine and Klinikum Rechts Der Isar, Department of Radiation Oncology, Technichal University of Munich (TUM), Munich, Germany.

K A Kessel (KA)

School of Medicine and Klinikum Rechts Der Isar, Department of Radiation Oncology, Technichal University of Munich (TUM), Munich, Germany.
Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Zentrum München (HMGU), Neuherberg, Germany.
Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany.

S Münch (S)

School of Medicine and Klinikum Rechts Der Isar, Department of Radiation Oncology, Technichal University of Munich (TUM), Munich, Germany.

S E Combs (SE)

School of Medicine and Klinikum Rechts Der Isar, Department of Radiation Oncology, Technichal University of Munich (TUM), Munich, Germany.
Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Zentrum München (HMGU), Neuherberg, Germany.
Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH